 | • レポートコード：MRC2302D111 • 出版社/出版日：Transparency Market Research / 2022年12月22日 • レポート形態：英語、PDF、120ページ • 納品方法：Eメール（受注後24時間以内） • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、2022年に27億ドルであった世界の前立腺癌低侵襲手術市場規模が2031年には39億ドルとなり、予測期間の間に年平均3.6％増加すると展望しています。本資料では、前立腺癌低侵襲手術の世界市場について徹底調査し、序論、仮定・調査方法、エグゼクティブサマリー、市場概要、主要インサイト、手術別（腹腔鏡手術、ロボット手術、放射線治療、冷凍手術、その他）分析、ステージ別（早期前立腺癌（ステージI・II）、局所進行性前立腺癌（ステージIII）、進行性前立腺癌（ステージIV））分析、エンドユーザー別（病院、専門クリニック、外来手術センター）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。本資料は、AngioDynamics、B. Braun SE、Becton, Dickinson and Company、Ethicon Endo-Surgery, Inc. (Johnson & Johnson Services, Inc.)、Intuitive Surgical、Medtronic、Olympus Corporation、Siemens Healthcare GmbH、Teleflex Incorporatedなどの企業情報を収録しています。 ・序論 ・仮定・調査方法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の前立腺癌低侵襲手術市場規模：手術別 - 腹腔鏡手術の市場規模 - ロボット手術の市場規模 - 放射線治療の市場規模 - 冷凍手術の市場規模 - その他の市場規模 ・世界の前立腺癌低侵襲手術市場規模：ステージ別 - 早期前立腺癌（ステージI・II）における市場規模 - 局所進行性前立腺癌（ステージIII）における市場規模 - 進行性前立腺癌（ステージIV）における市場規模 ・世界の前立腺癌低侵襲手術市場規模：エンドユーザー別 - 病院における市場規模 - 専門クリニックにおける市場規模 - 外来手術センターにおける市場規模 ・世界の前立腺癌低侵襲手術市場規模：地域別 - 北米の前立腺癌低侵襲手術市場規模 - ヨーロッパの前立腺癌低侵襲手術市場規模 - アジア太平洋の前立腺癌低侵襲手術市場規模 - 中南米の前立腺癌低侵襲手術市場規模 - 中東・アフリカの前立腺癌低侵襲手術市場規模 ・競争状況 |
Prostate Cancer Minimally Invasive Surgery Market – Scope of Report
TMR’s report on the global prostate cancer minimally invasive surgery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global prostate cancer minimally invasive surgery market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global prostate cancer minimally invasive surgery market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the prostate cancer minimally invasive surgery market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global prostate cancer minimally invasive surgery market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global prostate cancer minimally invasive surgery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global prostate cancer minimally invasive surgery market.
The report delves into the competitive landscape of the global prostate cancer minimally invasive surgery market. Key players operating in the global prostate cancer minimally invasive surgery market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global prostate cancer minimally invasive surgery market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market prostate cancer minimally invasive surgery.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Prostate Cancer Minimally Invasive Surgery Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Prostate Cancer Minimally Invasive Surgery Market Value Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Regulatory Scenario by Region/Globally
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long-term Impact)
6. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Procedure
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Procedure, 2017–2031
6.3.1. Laparoscopic Surgery
6.3.2. Robotic Surgery
6.3.3. Radiation Therapy
6.3.4. Cryosurgery
6.3.5. Others
6.4. Market Attractiveness Analysis, by Procedure
7. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Stage
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Stage, 2017–2031
7.3.1. Early-stage Prostate Cancer (Stages I and II)
7.3.2. Locally Advanced Prostate Cancer (Stage III)
7.3.3. Advanced Prostate Cancer (Stage IV)
7.4. Market Attractiveness Analysis, by Stage
8. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Ambulatory Surgery Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Procedure, 2017–2031
10.2.1. Laparoscopic Surgery
10.2.2. Robotic Surgery
10.2.3. Radiation Therapy
10.2.4. Cryosurgery
10.2.5. Others
10.3. Market Value Forecast, by Stage, 2017–2031
10.3.1. Early-stage Prostate Cancer (Stages I and II)
10.3.2. Locally Advanced Prostate Cancer (Stage III)
10.3.3. Advanced Prostate Cancer (Stage IV)
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Ambulatory Surgery Centers
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Procedure
10.6.2. By Stage
10.6.3. By End-user
10.6.4. By Country
11. Europe Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Procedure, 2017–2031
11.2.1. Laparoscopic Surgery
11.2.2. Robotic Surgery
11.2.3. Radiation Therapy
11.2.4. Cryosurgery
11.2.5. Others
11.3. Market Value Forecast, by Stage, 2017–2031
11.3.1. Early-stage Prostate Cancer (Stages I and II)
11.3.2. Locally Advanced Prostate Cancer (Stage III)
11.3.3. Advanced Prostate Cancer (Stage IV)
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Ambulatory Surgery Centers
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Procedure
11.6.2. By Stage
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Procedure, 2017–2031
12.2.1. Laparoscopic Surgery
12.2.2. Robotic Surgery
12.2.3. Radiation Therapy
12.2.4. Cryosurgery
12.2.5. Others
12.3. Market Value Forecast, by Stage, 2017–2031
12.3.1. Early-stage Prostate Cancer (Stages I and II)
12.3.2. Locally Advanced Prostate Cancer (Stage III)
12.3.3. Advanced Prostate Cancer (Stage IV)
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Ambulatory Surgery Centers
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Procedure
12.6.2. By Stage
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Procedure, 2017–2031
13.2.1. Laparoscopic Surgery
13.2.2. Robotic Surgery
13.2.3. Radiation Therapy
13.2.4. Cryosurgery
13.2.5. Others
13.3. Market Value Forecast, by Stage, 2017–2031
13.3.1. Early-stage Prostate Cancer (Stages I and II)
13.3.2. Locally Advanced Prostate Cancer (Stage III)
13.3.3. Advanced Prostate Cancer (Stage IV)
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Ambulatory Surgery Centers
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Procedure
13.6.2. By Stage
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Procedure, 2017–2031
14.2.1. Laparoscopic Surgery
14.2.2. Robotic Surgery
14.2.3. Radiation Therapy
14.2.4. Cryosurgery
14.2.5. Others
14.3. Market Value Forecast, by Stage, 2017–2031
14.3.1. Early-stage Prostate Cancer (Stages I and II)
14.3.2. Locally Advanced Prostate Cancer (Stage III)
14.3.3. Advanced Prostate Cancer (Stage IV)
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Ambulatory Surgery Centers
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Procedure
14.6.2. By Stage
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. AngioDynamics
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. B. Braun SE
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Becton, Dickinson and Company
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Ethicon Endo-Surgery, Inc. (Johnson & Johnson Services, Inc.)
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Intuitive Surgical
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Medtronic
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Olympus Corporation
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Siemens Healthcare GmbH
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Teleflex Incorporated
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Product Portfolio
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview